24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy

      1 , 2 , 1 , 2 , 3 , 2 , 4 , 5 , 6 , 7 , 8 , 4 , 9 , 9 , 10 , 6 , 4 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 2 , 18 , 19 , 20 , 21 , 22 , 23 , 1 , 2 , 24 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 1 , 2 , for the Movement Disorder Society‐endorsed PSP Study Group
      Movement Disorders
      Wiley

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

          PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson's syndrome.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Progressive Supranuclear Palsy

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

              PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. Our aim was to critically evaluate the degree to which structural, functional and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP.
                Bookmark

                Author and article information

                Journal
                Movement Disorders
                Mov Disord
                Wiley
                0885-3185
                1531-8257
                June 18 2019
                August 2019
                March 18 2019
                August 2019
                : 34
                : 8
                : 1228-1232
                Affiliations
                [1 ]Department of NeurologyTechnische Universität München Munich Germany
                [2 ]German Center for Neurodegenerative Diseases (DZNE) Munich Germany
                [3 ]Second Department of NeurologyAttikon University Hospital, University of Athens Athens Greece
                [4 ]Center for Neuropathology and Prion ResearchLudwig‐Maximilians‐Universität Munich Germany
                [5 ]Department of Psychiatry and PsychotherapyUniversity Hospital, LMU Munich Munich Germany
                [6 ]Division of NeurologyRoyal University Hospital, University of Saskatchewan Saskatoon Saskatchewan Canada
                [7 ]Neurological Tissue Bank and Neurology DepartmentHospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CERCA Barcelona Catalonia Spain
                [8 ]Institute of Neurology, Medical University of Vienna Vienna Austria
                [9 ]Frontotemporal Degeneration Center, Department of NeurologyUniversity of Pennsylvania Philadelphia Pennsylvania USA
                [10 ]Department of NeurologyJohns Hopkins University Baltimore Maryland USA
                [11 ]Department of NeurologyErasmus Medical Centre Rotterdam The Netherlands
                [12 ]London Neurodegenerative Diseases Brain BankInstitute of Psychiatry, Psychology and Neuroscience, Kings College London London UK
                [13 ]Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, and Department of NeurosciencesPadova University Padova Italy
                [14 ]Sobell Department of Motor Neuroscience and Movement DisordersUCL Institute of Neurology Queen Square London UK
                [15 ]Department of NeurologySanta Maria University Hospital of Terni Terni Italy
                [16 ]Departments of Nuclear Medicine and NeurologyUniversity of Cologne Cologne Germany
                [17 ]Department of NeurologyUniversity of Ulm Ulm Germany
                [18 ]Department of NeurologyLudwig‐Maximilians‐Universität Munich Germany
                [19 ]Univ. de Bordeaux, Institut des Maladies Neurodégénératives UMR 5293, Bordeaux France
                [20 ]Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux Bordeaux France
                [21 ]Dept. MedicineUniversity of Otago, Christchurch, and New Zealand Brain Research Institute Christchurch New Zealand
                [22 ]Department of Clinical Sciences, Division of NeurologyLund University Lund Sweden
                [23 ]Department of NeurologyPhilipps Universität Marburg Germany
                [24 ]Department of NeurologyMedical University Innsbruck Innsbruck Austria
                [25 ]Memory and Aging Center, Department of NeurologyUniversity of California San Francisco California USA
                [26 ]Department of NeurologyRutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA
                [27 ]Department of NeurologyMayo Clinic Rochester Minnesota USA
                [28 ]Department of NeurologyUniversity of California San Diego California USA
                [29 ]Department of Clinical NeuroscienceUCL Institute of Neurology Queen Square London UK
                [30 ]Department of RadiologyMayo Clinic Rochester Minnesota USA
                [31 ]Parkinson's Disease & Movement Disorders UnitHospital Clínic/IDIBAPS/CIBERNED/European Reference Network for Rare Neurological Diseases (ERN‐RND)/Institut de Neurociències, Universitat de Barcelona Barcelona Catalonia Spain
                [32 ]Sorbonne Université, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, ICM, Hôpital Pitié‐SalpêtrièreDepartment of Neurology Paris France
                [33 ]The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital Toronto Ontario Canada
                [34 ]Department of Clinical Neurosciences and Cambridge Centre for Parkinson‐PlusCambridge University Cambridge UK
                Article
                10.1002/mds.27666
                6699888
                30884545
                e1114ff4-dab5-491c-bbca-70a2092b0326
                © 2019

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                http://doi.wiley.com/10.1002/tdm_license_1.1

                History

                Comments

                Comment on this article